HR 158

Abstract

Directs the Auditor General to conduct a comprehensive investigation of the utilization of the 340B Drug Pricing Program by covered entities within Illinois to assess the amount of 340B profit, defined as total patient and payer reimbursement less the total 340B acquisition cost, generated by 340B covered entities from both self-administered and physician-administered drugs, the amount spent on third party administrators for the management of the 340B Program, the amount going to pharmacy benefit managers (PBM) in contract pharmacy arrangements, the amount going to contract pharmacies, whether covered entities maintain title to 340B drugs in contract pharmacy locations, the average mark-up imposed by covered entities on 340B priced drugs, and the extent to which 340B entities pass 340B discounts to vulnerable patients at the point of sale for both in-house and contracted pharmacies and to also examine the impact of these practices on state health programs, such as Medicaid and the State Employees Group Insurance Program, and to make recommendations for improvement.